Health tech startup Quibim is closing in on its goal to take precision medicine to the next level via advanced imaging technology after a US$50m fundraise.
The Spanish enterprise’s long-term ambition is a system in which clinicians can gain a non-invasive understanding of every tissue point in the human body, at any moment in time.
To achieve this it has developed AI models which can be applied to imaging that extract actionable insights from MRI, CT, and PET scans. These insights enable precise characterisation of phenotypes and prediction of outcomes in areas such as oncology, immunology, neurology and metabolic disorders.
This is the pathway toward achieving human digital twins, dynamic models that not only reflect and allow health monitoring but also enhance patient stratification, improve the success rates of drug development programmes, and enable treatment testing before application.
Today, it is building digital twins at the organ and lesion level but, as the volume of whole-body scans and related imaging data continues to grow, Quibim models could eventually analyse the entire body.
Currently it has 170 installations worldwide and regulatory clearances across the US, EU, UK, and other regions.
Last year, Philips signed a global partnership with Quibim to integrate its AI models into MR scanners, while the company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.
Today the company announced the closing of its US$50m series A funding round.
CEO and co-founder Dr Ángel Alberich-Bayarri said: “Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support.
“Our global expansion into the US is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionise diagnostics and improve patient outcomes.”
The financing was led by Asabys and Buenavista Equity Partners, with UI Investissements and GoHub Ventures joining as new investors.
Current investors involved in the round included Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind and Tony Fadell’s Build Collective, and individual investor Dr Jonathan Milner, founder of Abcam plc.
Pictured above: L-R: Alberto Valiente, COO, Ángel Alberich-Bayarri, CEO, and Javier Sáez, VP finance & business intelligence, of Quibim. (credit: Quibim)
